The role of BAFF in immune function and implications for autoimmunity

Immunological Reviews

Volumn 204, Issue , 2005, Pages 43-54

  Kalled, Susan L ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR INHIBITOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BELIMUMAB; CELL SURFACE PROTEIN; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C3D RECEPTOR; FC RECEPTOR; LIGAND; MONOCLONAL ANTIBODY; PROTEIN INHIBITOR; RITUXIMAB; TRANSMEMBRANE ACTIVATOR AND CALCIUM MODULATOR AND CYCLOPHILIN LIGAND INTERACTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL SURVIVAL; CLINICAL TRIAL; DISEASE MODEL; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL SURVIVAL; HUMANS; MEMBRANE PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 16244423682     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00219.x     Document Type: Review

References (80)

1. Gorman C, Leandro M, Isenberg D. B cell depletion in autoimmune disease. Arthritis Res Ther 2003;5:S17-S21.
2. Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum 2003;49:394-398.
3. Kalled SL, Ambrose C, Hsu YM, BAFF: B cell survival factor and emerging therapeutic target for autoimmune disorders. Expert Opin Ther Targets 2003;7:115-123.
4. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003;21:231-264.
5. Kalled SL, Ambrose C, Hsu YM. The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun (in press).
6. Nardelli B, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2000;97:198-204.
7. Scapini P, et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003;197:297-302.
8. Huard B, et al. BAFF production by antigen-presenting cells provides T cell co-stimulation. Int Immunol 2004;16:467-475.
9. Hase H, et al. BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 2004;103:2257-2265.
10. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003;198:937-945.
11. Thompson JS, et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001;293:2108-2111.
12. Ng LG, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004;173:807-817.
13. Gorelik L, et al. Cutting edge: BAFF regulates CD21/35 and CD23 expression independent of its B cell survival function. J Immunol 2004;172:762-766.
14. Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002;168:5993-5996.
15. Schiemann B, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001;293:2111-2114.
16. Gross JA, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 2001;15:289-302.
17. Shulga-Morskaya S, et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004;173:2331-2341.
18. Gras MP, et al. BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol 1995;7:1093-1106.
19. Avery DT, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003;112:286-297.
20. Novak AJ, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004;103:689-694.
21. von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997;278:138-141.
22. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001;14:573-582.
23. Yan M, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2001;2:638-643.
24. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003;18:279-288.
25. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000;10:785-788.
26. Wu Y, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000;275:35478-35485.
27. Yan M, et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr Biol 2001;11:1547-1552.
28. Tan SM, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003;48:982-992.
29. Roschke V, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314-4321.
30. Stohl W, et al. Inverse association between circulating APRIL levels and serologic and clinical disease activities in patients with systemic lupus erythematosus. Ann Rheum Dis 2004;63:1096-1103.
31. Stein JV, et al. APRIL modulates B and T cell immunity. J Clin Invest 2002;109:1587-1598.
32. Castigli E, et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004;101:3903-3908.
33. Varfolomeev E, et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004;24:997-1006.
34. Schneider P, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-1756.
35. Mackay F, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999;190:1697-1710.
36. Gross JA, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000;404:995-999.
37. Khare SD, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000;97:3370-3375.
38. Groom J, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109:59-68.
39. Rahman ZS, Rao SP, Kalled SL, Mauser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003;198:1157-1169
40. Vora KA, et al. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to die TNF family exhibit impaired maturation and function. J Immunol 2003;171:547-551.
41. Batten M, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med 2000;192:1453-1466.
42. Cyster JG, Hartley SB, Goodnow CC. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 1994;371:389-395.
43. Mason DY, Jones M, Goodnow CC. Development and follicular localization of tolerant B lymphocytes in lysozyme/anti-lysozyme IgM/IgD transgenic mice. Int Immunol 1992;4:163-170.
44. Cyster JG, Goodnow CC. Antigen-induced exclusion from follicles and anergy are separate and complementary processes that influence peripheral B cell fate. Immunity 1995;3:691-701.
45. Ekland EH, Forster R, Lipp M, Cyster JG. Requirements for follicular exclusion and Bulletcompetitive elimination of autoantigen-binding B cells. J Immunol 2004;172:4700-4708.
46. Lesley R, et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004;20:441-453.
47. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med 2003;198:1119-1126.
48. Thien M, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-798.
49. Kurtz CB, O'Toole E, Christensen SM, Weis JH. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J Immunol 1990;144:3581-3591.
50. Molina H, Kinoshita T, Inoue K, Carel JC, Holers VM. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol 1990;145:2974-2983.
51. Carroll MC. The complement system in B cell regulation. Mol Immunol 2004;41:141-146.
52. Boackle SA, Holers VM. Role of complement in the development of autoimmunity. Curr Dir Autoimmun 2003;6:154-168.
53. Takahashi K, et al. Mouse complement receptors type 1 (CR1; CD35) and type 2 (CR2; CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol 1997;159:1557-1569.
54. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992;256:105-107.
55. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996;93:2264-2271.
56. + T cells. Nature 1995;376:181-184.
57. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996;87:319-329.
58. Fischer MB, et al. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 1998;280:582-585.
59. Boackle SA, et al. Cr2, a candidate gene in the murine Sle 1c lupus susceptibility locus, encodes a dysfunctional protein. Immunity 2001;15:775-785.
60. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001;44:1313-1319.
61. Zhang J, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
62. Stohl W, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-3486.
63. Mariette X, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-171.
64. Lavie F, Miceli-Richard C, Quillard J, Roux S, Ledere P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 2004;202:496-502.
65. Qin Y, Duquette P. B-cell immunity in MS. Int MS J 2003;10:110-120.
66. Qin Y, Duquette P, Zhing Y, Talbot P, Poole R, Antel J. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998;102:1045-1050.
67. Baranzini SE, Jeong MC, Butunoi C, Murray RS, Bernard CC, Oksenberg JR. B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. J Immunol 1999;163:5133-5144.
68. Colombo M, et al. Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients. J Immunol 2000;164:2782-2789.
69. Thangarajh M, Gomes A, Masterman T, Hillert J, Hjelmstrom P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 2004;152:183-190.
70. Kayagaki N, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002;17:515-524.
71. Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2004;148:11-23.
72. Schneider P, et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med 2001;194:1691-1697.
73. Wang H, et al. TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice. Nat Immunol 2001;2:632-637.
74. Martin F, Chan AC. Pathogenic roles of B cells in human autoimmunity: insights from the clinic. Immunity 2004;20:517-527.
75. O'Connor BP, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-98.
76. Morel L, Yu Y, Blenman KR, Caldwell RA, Wakeland EK. Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm Genome 1996;7:335-339.
77. Rozzo SJ, et al. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity 2001;15:435-443.
78. + T cells: lessons from HIV-infected patients. Clin Immunol 2002;104:115-122.
79. Rodriguez B, Valdez H, Freimuth W, Butler T, Asaad R, Lederman MM. Plasma levels of B-lymphocyte stimulator increase with HIV disease progression. Aids 2003;17:1983-1985.
80. Huard B, Schneider P, Mauri D, Tschopp J, French LE. T cell costimulation by the TNF ligand BAFF. J Immunol 2001;167:6225-6231.